Loading...

HEPION PHARMACEUTICALS INC Delisting Actions 8-K Filing

HPN

HEPION PHARMACEUTICALS INC

()

2024 8-K

Management Change

License Agreement

Management Change

Asset Acquisitions

Forced Delisting

Asset Acquisitions

Balance Sheet Update

Equity Financing

Financial Update

Clinical Trial Update

Nasdaq Compliance Notice

Management Changes

Merger Agreement

Appointment of Director

Management Changes

Registered Direct Offering ...

Resignation of Director

Dismissal of BDO USA, P.C. ...

Resignation of CEO and Rest...

Securities Purchase Agreement

Investor Meetings

Equity Offerings

Annual Meeting of Stockholders

Regulation FD Disclosure, O...

Reverse Stock Split

External Links:

Hepion Pharmaceuticals received a notice from Nasdaq for failing to meet listing requirements due to a stockholders deficit of $406,685 and insufficient market value or net income, giving them 45 days to submit a compliance plan.

AI Assistant

HEPION PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.